Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Will Use Accelrys Software to Speed Drug Discovery

NEW YORK, Jan. 29 - Accelrys has struck a global licensing agreement with AstraZeneca, the informatics firm said on Tuesday.

 

Terms of the deal call for AstraZeneca researchers to use Accelrys software to understand therapeutic target and to identify and optimize lead compounds, said Accelrys, a Pharmacopeia unit.

 

Financial details of the agreement were not disclosed.

 

The arrangement covers scientists at 10 research sites worldwide, including Montreal; Bangalore, India; Södertalje, Lund, and Mölndal, in Sweden; and Wilmington, Del., and Boston, in the US.

 

All researchers will have access to Accelrys software libraries for modeling and simulation.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.